NervGen Dosed First Participant in Spinal Cord Study
The Phase 3 RESTORE study will test the efficacy of NVG-291 in adults with cervical spinal cord injuries.
Updated on Oct. 12, 2026 in Stroke
Live Poll
Should clinical trials for spinal cord injuries prioritize functional recovery improvements over other treatment outcomes?
NervGen has officially dosed the first participant in its RESTORE Phase 3 registrational study, which evaluates the safety and efficacy of the drug NVG-291. This clinical trial aims to assess improvements in hand function for adults living with chronic cervical motor-incomplete spinal cord injuries.
Why it matters
The study design follows promising functional results observed in earlier phases, seeking to address a major gap in treatment options for patients with long-term spinal cord injuries. The outcome could establish a new standard of care if the therapeutic approach demonstrates significant efficacy.
The study enrolls 150 adults who will receive daily subcutaneous injections over a 12-week treatment period. Investigators will subsequently monitor participants during a four-week observation phase to measure recovery using the GRASSP scale.
The players
NervGen
A clinical-stage biotechnology company focused on developing therapies for nervous system damage.
Food and Drug Administration
The U.S. federal agency responsible for regulating medical products and granting drug designations like Fast Track status.
European Medicines Agency
An agency of the European Union that oversees the evaluation and supervision of pharmaceutical products.
The details
The randomized, double-blind, placebo-controlled trial focuses on individuals one to ten years post-injury with a motor level of C7 or higher. Participants receive the experimental drug or a placebo daily, with an optional open-label extension available after the initial study window concludes.
Timeline
October 12, 2026: The first participant was dosed for the RESTORE Phase 3 study.
Second half of 2027: NervGen anticipates completing patient enrollment for the trial.
First half of 2028: The company expects to report topline study data.
The Big Picture
The RESTORE study extends the research trajectory established by the CONNECT SCI study into a larger Phase 3 registrational environment. This trial marks a critical effort to move experimental neuro-regenerative therapies toward potential regulatory approval.
This trial offers a potential new treatment pathway for patients currently living with chronic spinal cord injuries. The study results will determine if daily subcutaneous injections can provide a safe and effective means to improve motor function in the future.
The takeaway
The initiation of this Phase 3 trial marks a pivotal move toward verifying whether NVG-291 can provide measurable functional recovery. Patients and providers should monitor official registry updates as the trial progresses toward its 2028 data readout.
What happens next
NervGen plans to complete enrollment in the second half of 2027 and release topline study data in the first half of 2028.
Further reading
For additional context on neurological recovery research, visit the Stroke section.
More information
Find complete clinical study information and eligibility lookup resources for this trial.
Live Poll
Should clinical trials for spinal cord injuries prioritize functional recovery improvements over other treatment outcomes?
